Vilastobart

DB19327InvestigationalProtein Based Therapies

Vilastobart is under investigation in clinical trial NCT04896697 (Vilastobart (XTX101) Monotherapy and Vilastobart and Atezolizumab Combination Therapy in Advanced Solid Tumors).

Mechanism: Pharmacologically active on Cytotoxic T-lymphocyte protein 4
Curator reviewed
Also known as: gamma1 heavy chain humanized (1-449) [VH (Homo sapiens IGHV1-69*08 (84.7%) -(IGHD) -IGHJ4*01 (92.9%), CDR-IMGT[8.8.12] (26-33.51-58.97-108)) (1-119) -Homo sapiens IGHG1*01, G1m17,1 CH1 K120, D12, L14, G1v7 CH2 D3, E117 (CH1 K120 (216) (120-217), hinge 1- · immunoglobulin G1-fused prodomain kappa, anti-[Homo sapiens CTLA4 (cytotoxic T-lymphocyte associated protein 4, CTLA-4, CD152)], humanized monoclonal antibody
Code names: XTX101

Resolves to

Compound

UNII8FUE2D4G82CAS2760549-50-4

Targets

P16410CTLA4

What you can answer from here — as of July 09, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

2Clinical trialsPhase, status and sponsor resolved per trial

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with Vilastobart, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account